Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cogent Biosciences Inc COGT

Healthcare Biotechnology
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:COGT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

PR Newswire 6 days ago

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

GlobeNewswire April 9, 2024

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 26, 2024

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

GlobeNewswire February 22, 2024

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

GlobeNewswire February 14, 2024

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

GlobeNewswire February 5, 2024

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

GlobeNewswire January 9, 2024

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

GlobeNewswire December 11, 2023
View More News ››

Opinion & Analysis (NDAQ:COGT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:COGT)

Cogent Biosciences Presents Data Highlighting Potential Best

Breaking News: $COGT Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR...
whytestocks - April 9, 2024

Cogent Biosciences Reports Recent Business Highlights and Fo

NEWS: $COGT Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results@ UMMIT Part 2...
whytestocks - February 26, 2024

Cogent Biosciences Reports Oversubscribed $225M PP

Just In: $COGT Cogent Biosciences Reports Oversubscribed $225M PP2024-02-14 09:31:30 ET DENVER, Colo., Feb. 14, 2024 ( www.247marketnews...
whytestocks - February 14, 2024

Cogent Biosciences Announces Closing of Upsized Public Offer

Just In: $COGT Cogent Biosciences Announces Closing of Upsized Public Offering of Common StockWALTHAM, Mass. and BOULDER, Colo., June 09...
whytestocks - June 9, 2023

COGENT BIOSCIENCES: MASSIVE UPSIDE POTENTIAL!

COGENT BIOSCIENCES: MASSIVE UPSIDE POTENTIAL! https://www.aviseanalytics.com/cogent-biosciences-massive-upside-potential/ Cogent...
AviseAnalytics - November 15, 2021

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!

5 STOCKS FOR YOUR INVESTMENT WATCHLIST!   CYCN COGT QIPT CHS POLY https://www.aviseanalytics.com/5-stocks-for-your...
AviseAnalytics - November 12, 2021
View more Bullboard ››

Voltage Metals Corp

Voltage Metals Corp

Voltage Metals Corp. is a Canada-based critical metals exploration and development company. The Company is focused on ...
View More »